These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32044644)

  • 1. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
    Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
    Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tivozanib in advanced renal cell carcinoma therapy.
    Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis.
    Manz KM; Fenchel K; Eilers A; Morgan J; Wittling K; Dempke WCM
    Adv Ther; 2020 Feb; 37(2):730-744. PubMed ID: 31838709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tivozanib: a new treatment option for renal cell carcinoma.
    Saes L; Eskens FALM
    Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
    Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
    Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
    Passi I; Billowria K; Kumar B; Chawla PA
    Anticancer Agents Med Chem; 2023; 23(5):562-570. PubMed ID: 35718972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Borchiellini D
    Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
    Cowey CL
    Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tivozanib for the treatment of metastatic renal cancer.
    Wong HH; Eisen T
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):649-60. PubMed ID: 23773100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
    Imano H; Kato R; Ijiri Y; Hayashi T
    Toxicol In Vitro; 2021 Mar; 71():105063. PubMed ID: 33271325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
    Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
    Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
    Bhargava P; Robinson MO
    Curr Oncol Rep; 2011 Apr; 13(2):103-11. PubMed ID: 21318618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
    Bæk Møller N; Budolfsen C; Grimm D; Krüger M; Infanger M; Wehland M; E Magnusson N
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
    Haaker L; Tryssesoone L; Renders I; Verbiest A; Lerut E; Baldewijns M; Bourgain C; Roussel E; Van den Bulck H; Wynendaele W; Laguerre B; Rioux-Leclercq N; Oudard S; Laenen A; Debruyne PR; Albersen M; Beuselinck B
    Urol Oncol; 2020 Aug; 38(8):686.e1-686.e9. PubMed ID: 32430250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
    Li J; Gu J
    Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
    Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
    Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
    Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
    Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.